Thursday May 23, 5:43 pm Eastern Time
Press Release
SOURCE: Biogen, Inc.
FDA Advisory Committee Recommends Approval of Biogen's AMEVIVE(R)
CAMBRIDGE, Mass., May 23 /PRNewswire-FirstCall/ -- Biogen, Inc. (Nasdaq: BGEN - News) today announced that the FDA's Dermatologic & Ophthalmic Drug Advisory Committee voted to recommend approval of AMEVIVE® (alefacept) for the treatment of moderate-to-severe chronic plaque psoriasis. (Photo: newscom.com )
Burt A. Adelman, M.D., Biogen's Executive Vice President of Research & Development, said, "This is an important step forward in the development of AMEVIVE. We are encouraged by the results of today's meeting and we look forward to continuing to work with FDA to bring AMEVIVE to market as a new treatment for psoriasis."
Psoriasis is a T-cell mediated inflammatory disorder of the skin that can cause considerable discomfort. It is a disease for which there is no cure, affecting people of all ages. According to the American Academy of Dermatology, psoriasis affects 3-5 million people in the United States and about another 100 million people worldwide. Although individuals with mild psoriasis can often control their disease with topical agents, more than one million patients worldwide require ultraviolet or systemic immunosuppressive therapy. According to the National Psoriasis Foundation, the disease impacts a person's psychological well being and social functioning as well as their physical functioning. |
